Clinical trial
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
NCT00199849 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00199849 |
|---|---|
| Title | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine |
| Official title | Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen. |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | New York Presbyterian Hospital M.D. Anderson Cancer Center Memorial Sloan Kettering Cancer Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma |
| Intervention type | Biological |
| Interventions | NY-ESO-1 Plasmid DNA Cancer Vaccine |
| Enrollment | 18 |
| Start date | Sep 27, 2004 |
| Primary completion | Sep 11, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 10, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: